NCT04805346Completed
Remote Ischemic Conditioning in Oncology
Remote Ischemic Conditioning for Protection from Treatment-related Cardiotoxicity in Pediatric, Adolescent, and Young Adult Patients Undergoing Anthracycline Chemotherapy
Source: ClinicalTrials.gov · Last updated 26 Sept 2024
Brief summary (registry, in English)
This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic conditioning (RIC) is feasible in children and young adults receiving anthracycline chemotherapy. The secondary purpose is to describe differences in markers of myocardial injury and stress in children and young adults that receive RIC prior to anthracycline chemotherapy compared to control subjects that receive sham therapy prior to chemotherapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 17 Mar 2021
- Start date
- 30 Apr 2021
- Primary completion date
- 1 Jul 2023
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Diseases
- Childhood cancers
- NCT number
- NCT04805346
What you commit to
- Study type: Interventional
- Participants enrolled: 1
- From 30 Apr 2021 to the primary completion date, 1 Jul 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of cardiomyopathy (dilated, hypertrophic, restrictive, myocarditis) or congenital heart disease other than bicuspid aortic valve.
Other illness
- Known peripheral vascular disease or vasculitis.
- Known clotting disorder or hypercoagulability
Lab values
- Chronic kidney disease as defined as a pre-transplant GFR \<80
- Platelet count less than 30,000.
Other
- Central line in both upper extremities.
- Non-English-speaking patients.
Who the study is looking for
- Pediatric, adolescent, or young adult patients, 11 years of age or above.
- Able to tolerate upper arm blood pressure inflation.
Age in the registry: 11 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cincinnati Children's Hospital Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.